Recent advances in AI for antimicrobial resistance (AMR) prevention and control

antimicrobial resistance; AI in healthcare; machine learning; antibiotic stewardship; AI antibiotic discovery; phage therapy; rapid diagnostics; AMR surveillance; generative AI

As Drug Resistance Rises, GramEye and GSK Advance New AI-Led Infectious Disease Research

antimicrobial resistance (AMR); GramEye; GSK; AI-driven drug discovery; Gram-negative bacteria; Staphylococcus aureus; fungal infections; novel antibiotics; superbugs; infectious disease research; clinical trials

US-Backed Group Reports Success with New Tuberculosis Treatment in Phase 2 Study

tuberculosis; TB Alliance; Phase 2 clinical trial; sorfequiline; SPaL regimen; pretomanid; linezolid; drug-resistant TB; ultra-short regimen; US support; clinical trial results

Pfizer Warns of ‘Near-Term Stock Out’ of Penicillin Used for Treating Syphilis in Pregnant Women After Recall

Pfizer; penicillin recall; Bicillin L-A; syphilis treatment; pregnant women; drug shortage; congenital syphilis; FDA; Extencilline; public health

FDA Approves UroGen’s Chemo-Turned-Gel Drug ZUSDURI Despite Negative Advisory Vote

UroGen; FDA approval; ZUSDURI; UGN-102; chemo-turned-gel drug; mitomycin gel; low-grade intermediate-risk non–muscle-invasive bladder cancer; negative AdComm vote; ENVISION trial; ODAC

GSK, Spero Report Major Phase 3 Win for UTI Antibiotic; Spero’s Stock Surges

GSK; Spero Therapeutics; tebipenem HBr; Phase 3 trial; UTI antibiotic; complicated urinary tract infection; PIVOT-PO trial; stock surge; clinical trial results; FDA submission

FDA Advisory Committee Narrowly Votes Against UroGen’s Bladder Cancer Drug, Calls for Further Studies

FDA; UroGen Pharma; UGN-102; bladder cancer; Oncologic Drugs Advisory Committee; mitomycin; RCT; non–muscle invasive bladder cancer; clinical trials